The Effects of Interferon α2b on Chemically-induced Peritoneal Fibrosis and on Peritoneal Tissue MMP-2 and TIMP-2 Levels in Rats

被引:2
|
作者
Ucar, E. [1 ]
Borazan, A. [1 ]
Semerci, E. [2 ]
Binici, D. N. [3 ]
Yaldiz, M. [4 ]
Aysal, A. [5 ]
Altug, E. [6 ]
Kuvandik, C. [7 ]
Huzmeli, C. [1 ]
Yetim, T. [1 ]
Canda, S. [4 ]
机构
[1] Erzurum Educ & Res Hosp, Dept Nephrol, Erzurum, Turkey
[2] Erzurum Educ & Res Hosp, Dept Gen Surg, Erzurum, Turkey
[3] Erzurum Educ & Res Hosp, Dept Internal Med, Erzurum, Turkey
[4] Mustafa Kemal Univ, Dept Pathol, TR-31100 Antakya, Turkey
[5] Dokuz Eylul Univ, Dept Pathol, Izmir, Turkey
[6] Mustafa Kemal Univ, Fac Vet Med, Dept Gen Surg, TR-31100 Antakya, Turkey
[7] Kirikhan Govt Hosp, Dept Infect Dis, Antakya, Turkey
关键词
PERITONEAL FIBROSIS; INTERFERON-alpha 2B (IFN-alpha 2B); CHLORHEXIDINE GLUCONATE; RATS; MATRIX METALLOPROTEINASE-2 (MMP-2); TISSUE INHIBITORS METALLOPROTEINASE-2 (TIMP-2); PARIETAL THICKENING; MATRIX METALLOPROTEINASES; DIALYSIS; DISEASE; INJURY; MARKER; MODEL;
D O I
10.1177/147323001003800121
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study investigated the effect of interferon alpha 2b on chlorhexidine gluconate (CH)-induced peritoneal fibrosis (PF) in rats and assessed peritoneal tissue levels of metalloproteinase (MMP)-2 and tissue inhibitors of metalloproteinases (TIMP)-2. Wistar albino rats (n = 8 per group) were treated as follows: control group, 3 ml/day of 0.9% saline intraperitoneally for 28 days; CH group, 0.1% CH (200 g [3 ml]/day) in 15% ethanol and 0.9% saline intra-peritoneally for 28 days; CH + interferon (IFN) group, CH (as above) plus pegylated IFN-alpha 2b 1.5 mu g/kg per week subcutaneously on days 0, 7, 14, 21 and 28; IFN group, pegylated IFN-alpha 2b (as above). Parietal peritoneum samples were obtained from the left anterior abdominal wall after 35 days. Parietal thickness, degree of vascular proliferation and inflammation, and MMP-2 and TIMP-2 levels were determined. The mean peritoneal thicknesses of the control, CH, CH + IFN and IFN groups were 7.02 +/- 3.89, 156.86 +/- 29.13, 59.88 +/- 22.1, 9.27 +/- 2.03 mu m, respectively. Pegylated IFN-alpha 2b decreased CH-induced expression of MMP-2 in the parietal peritoneum, but had no effect on TIMP-2 levels. Further studies are needed to determine the optimal dosage and duration for pegylated IFN-alpha 2b treatment.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 50 条
  • [31] MMP-2 and TIMP-2 in the prostates of male and female mongolian gerbils: effects of hormonal manipulation
    Rochel-Maia, Sabrina S.
    Santos, Fernanda C. A.
    Vilamaior, Patrcia S. L.
    Justulin, Luis A., Jr.
    Felisbino, Sergio L.
    Goes, Rejane M.
    Taboga, Sebastiao R.
    HISTOLOGY AND HISTOPATHOLOGY, 2011, 26 (11) : 1423 - 1434
  • [32] Effects of therapy with two combinations of antibiotics on the imbalance of MMP-2/TIMP-2 in chronic periodontitis
    Bataiosu, Marilena
    Taisescu, Citto Iulian
    Pisoschi, Catalina Gabriela
    Pascu, Eugen Ionut
    Tuculina, Mihaela Jana
    Daguci, Luminita
    Daguci, Constantin
    Banita, Ileana Monica
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2015, 56 (01): : 77 - 83
  • [33] Effects of estrogen and progestin on expression of MMP-2 and TIMP-2 in a nude mouse model of endometriosis
    Wang, J.
    Ma, X.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2012, 39 (02): : 229 - 233
  • [34] Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients
    Lawicki, Slawomir
    Zajkowska, Monika
    Glazewska, Edyta Katarzyna
    Bedkowska, Grazyna Ewa
    Szmitkowski, Maciej
    BIOMARKERS, 2017, 22 (02) : 157 - 164
  • [35] Clinicopathological assessment & quantitative estimation of MMP-2, MMP-7, TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples
    Holubec, Lubos
    Pesta, Martin
    Finek, Jindrich
    Topolcan, Oldrich
    Holubec, Lubos
    Ruprt, Karel
    Treska, Vaclav
    ANNALS OF ONCOLOGY, 2006, 17 : 255 - 255
  • [36] Rosuvastatin reduces MMP-2 and-9 and increases TIMP-2 levels in patients with heart failure
    Andreou, I.
    Tousoulis, D.
    Vasiliadou, C.
    Tentolouris, C.
    Antoniades, C.
    Tsioufis, C.
    Brili, S.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2008, 29 : 768 - 768
  • [37] Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
    Davidson, B
    Reich, R
    Berner, A
    Givant-Horwitz, V
    Goldberg, I
    Risberg, B
    Kristensen, GB
    Trope, CG
    Bryne, M
    Kopolovic, J
    Nesland, JM
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) : 2040 - 2049
  • [38] Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor, TIMP-2, in patients with chronic heart failure
    Kobusiak-Prokopowicz, M.
    Krzysztofik, J.
    Kaaz, K.
    Jolda-Mydlowska, B.
    Mysiak, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 297 - 297
  • [39] Metalloproteinases MMP-9, MMP-2 and their tissue inhibitors TIMP-1, TIMP-2 in peripheral transbronchial lung biopsies of patients with sarcoidosis
    Piotrowski, Wojciech J.
    Nawrocka-Kunecka, Agnieszka
    Antczak, Adam
    Marczak, Jerzy
    Biernacki, Romuald
    Kordek, Piotr
    Kurmanowska, Zofia
    Gorski, Pawel
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (10): : 628 - 634
  • [40] Serum matrix metalloproteinases MMP-2 and MMP-9 and metal loproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy
    Rysz, Jacek
    Banach, Maciej
    Stolarek, Robert A.
    Pasnik, Jaroslaw
    Cialkowska-Rysz, Aleksandra
    Koktysz, Robert
    Piechota, Mariusz
    Baj, Zbigniew
    JOURNAL OF NEPHROLOGY, 2007, 20 (04) : 444 - 452